Literature DB >> 16257178

Redefining the HLA and RA association: to be or not to be anti-CCP positive.

René R P de Vries1, Tom W J Huizinga, René E M Toes.   

Abstract

Rheumatoid Arthritis (RA) is the most common chronic inflammatory joint disease. The overall prevalence is 1% and in people older than 60 it is more than 2%. RA has auto-immune features: auto-antibodies against the Fc part of IgG, so-called Rheumatoid Factor (RF) are found more often in RA patients and more recently RA-specific auto-antibodies directed against Cyclic Citrunilated Peptides (CCP) have been discovered. Based on twin studies the contribution of genetic factors to the pathogenesis has been estimated to be about 60%. The main genetic contribution (about 40%) comes from the HLA complex. An association between HLA-DR4 and RA was already documented almost 30 years ago. This association was more prominent for severe forms of the disease. Because more HLA-DRB1 alleles appeared to be associated with RA and the products of these alleles shared a 5AA sequence in a peptide-binding pocket the so-called Shared Epitope (SE) hypothesis was formulated, the prediction being that these DRB1 molecules would bind an RA inducing peptide(s). Thus far however such (a) peptides remain elusive. Because the risk for RA associated with different but SE-identical DRB1 alleles varies considerably this SE can also not be the whole explanation for the HLA contribution to RA susceptibility/severity. A modified SE has been postulated and a role for DQ has been postulated. There is also evidence for a contribution of non-class II genes to susceptibility. About 5 years ago we have reported that certain HLA-DRB1 alleles are associated with protection from (severe) RA. The products of these alleles carry instead of the SE sequence another peptide anchor region consisting of the amino acid DERAA. In a large prospective cohort study we showed recently that these alleles indeed confer (dominant) protection both against developing RA and a severe course of the disease. This protection was observed both in the presence and the absence of SE susceptibility alleles. We are presently exploring the hypothesis that this protection is mediated by regulatory T cells reactive with the DERAA epitope. An obvious way to unravel the apparently complex association between HLA and RA is to reduce the heterogeneity of this multifactorial disease. Recently, we have discovered that SE positive DRB1 alleles are exclusively associated with CCP positive RA. The previously reported association with RF positive RA appeared to be secondary to the association with anti-CCP pos. RA. This was the case both for the association found for susceptibility and severity. Interestingly, DRB1*03 was exclusively associated with anti-CCP neg. RA. Because recent evidence puts the immune response against citrunilated proteins (CCP) as prime suspect for disease induction and progression in this subgroup of RA these observations are a big leap forwards in solving the HLA-RA puzzle.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257178     DOI: 10.1016/j.jaut.2005.09.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  18 in total

1.  Highly conserved CDR3 region in circulating CD4(+)Vβ5(+) T cells may be associated with cytotoxic activity in Chagas disease.

Authors:  C A S Menezes; A K Sullivan; M T Falta; D G Mack; B M Freed; M O C Rocha; K J Gollob; A P Fontenot; W O Dutra
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice.

Authors:  Alexei von Delwig; Daniel M Altmann; Fraser G Charlton; Norman McKie; John D Isaacs; Rikard Holmdahl; John H Robinson
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

3.  In ACPA-positive RA patients, antibodies to EBNA35-58Cit, a citrullinated peptide from the Epstein-Barr nuclear antigen-1, strongly cross-react with the peptide β60-74Cit which bears the immunodominant epitope of citrullinated fibrin.

Authors:  M Cornillet; E Verrouil; A Cantagrel; G Serre; L Nogueira
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

4.  A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis.

Authors:  Vidya S Limaye; Sue Lester; Peter Bardy; Philip Thompson; Sally Cox; Peter Blumbergs; Peter Roberts-Thomson
Journal:  Rheumatol Int       Date:  2010-12-02       Impact factor: 2.631

5.  Perinatal and early childhood risk factors associated with rheumatoid factor positivity in a healthy paediatric population.

Authors:  Kendra A Young; Lezlie A Parrish; Gary O Zerbe; Marian Rewers; Kevin D Deane; V Michael Holers; Jill M Norris
Journal:  Ann Rheum Dis       Date:  2007-02       Impact factor: 19.103

Review 6.  To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice.

Authors:  Marshall Behrens; Michele Smart; David Luckey; Harvinder Luthra; Veena Taneja
Journal:  J Autoimmun       Date:  2011-06-12       Impact factor: 7.094

Review 7.  MicroRNAs as biomarkers in rheumatic diseases.

Authors:  Ilias Alevizos; Gabor G Illei
Journal:  Nat Rev Rheumatol       Date:  2010-06-01       Impact factor: 20.543

8.  Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis.

Authors:  Rachel Knevel; Saskia le Cessie; Chikashi C Terao; Kamil Slowikowski; Jing Cui; Tom W J Huizinga; Karen H Costenbader; Katherine P Liao; Elizabeth W Karlson; Soumya Raychaudhuri
Journal:  Sci Transl Med       Date:  2020-05-27       Impact factor: 17.956

9.  Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor.

Authors:  Alejandro Balsa; Arancha Cabezón; Gisela Orozco; Tatiana Cobo; Eugenia Miranda-Carus; Miguel Angel López-Nevot; José Luis Vicario; Emilio Martín-Mola; Javier Martín; Dora Pascual-Salcedo
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

10.  Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.

Authors:  Paula J Whittington; Olga Radkevich-Brown; Jennifer B Jacob; Richard F Jones; Amy M Weise; Wei-Zen Wei
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.